Prof. Weimin Xie 谢伟敏
Chief Physician, Professor
Department of Medical Oncology I, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized medical treatment for breast cancer, lung cancer, bone and soft tissue tumors, and gastrointestinal tumors, including chemotherapy and targeted therapy.
Dr. Xie is Chief Physician, Professor, and Master’s Supervisor at Guangxi Medical University Cancer Hospital. Dr. Xie leads the Department of Medical Oncology for Breast, Bone, and Soft Tissue Tumors. Research focuses on tumor drug resistance and genetic susceptibility, with funding from the National Natural Science Foundation. Dr. Xie has published over 80 academic papers and received four scientific achievement awards.
Professional roles
- Chair, Guangxi Tumor Chemotherapy Quality Control Center
- Chair, Oncology Branch of Guangxi Immunological Society
- Chair, Tumor Biological Therapy Professional Committee, Guangxi Anti-Cancer Association
- Vice Chair, Tumor Rehabilitation and Palliative Care Professional Committee, Guangxi Anti-Cancer Association
Name order: in Chinese the family name comes first (Xie Weimin). Papers usually list the name as Weimin Xie or Xie W.
Selected publications
16 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Breast Cancer, 2025 (senior author): Real-World Outcomes of Pyrotinib-Based Therapy for HER2-Positive Breast Cancer With Brain Metastases: A Multicentre, Retrospective Analysis. PubMed 39603902
- Medicine (Baltimore), 2024 (senior author): First-line carboplatin-based chemotherapy may be beneficial for HER2-low advanced breast cancer: A retrospective analysis. PubMed 39969377
- Pathol Oncol Res, 2022 (senior author): Prognostic value of long non-coding RNA MALAT1 in hepatocellular carcinoma: A study based on multi-omics analysis and RT-PCR validation. PubMed 36685103
- Ann Palliat Med, 2021 (senior author): Efficacy and safety of continuous infusion of Rh-endostatin combined with platinum-based chemotherapy for advanced triple-negative breast cancer. PubMed 35016411
- Onco Targets Ther, 2020 (senior author): Expression and Clinical Significance of ERCC1 and XPF in Human Hepatocellular Carcinoma. PubMed 32099408
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion